Daiichi Sankyo
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Daiichi Sankyo and other ETFs, options, and stocks.About DSNKY
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin.
CEOHiroyuki Okuzawa
CEOHiroyuki Okuzawa
Employees19,765
Employees19,765
HeadquartersTokyo, Tokyo
HeadquartersTokyo, Tokyo
Founded2005
Founded2005
Employees19,765
Employees19,765
DSNKY Key Statistics
Market cap33.03B
Market cap33.03B
Price-Earnings ratio15.64
Price-Earnings ratio15.64
Dividend yield2.26%
Dividend yield2.26%
Average volume206.43K
Average volume206.43K
High today$17.44
High today$17.44
Low today$17.03
Low today$17.03
Open price$17.03
Open price$17.03
Volume203.68K
Volume203.68K
52 Week high$28.21
52 Week high$28.21
52 Week low$17.03
52 Week low$17.03
DSNKY News
TipRanks 2d
Merck, Daiichi Sankyo granted priority review for ifinatamab deruxtecan BLADaiichi Sankyo (DSNKY) and Merck’s (MRK) Biologics License Application for ifinatamab deruxtecan has been accepted and granted Priority Review by the U.S. Food...
Analyst ratings
94%
of 16 ratingsBuy
93.8%
Hold
6.3%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.